Company Valuation: NFL Biosciences

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025
Market Cap 1 12.56 10.29 11.67 19.12 14.93
Change - -18.12% 13.49% 63.78% -21.92%
Enterprise Value (EV) 1 9.443 9.155 9.206 17.05 13.31
Change - -3.05% 0.56% 85.17% -21.93%
P/E -12.8x -4.21x -3.14x -9.56x -4.62x
PBR 3.82x 12.2x 33.6x 19.8x 48.8x
PEG - -0x 1.88x 0.2x -0.2x
Capitalization / Revenue 3,22,130x 4,67,546x 58.4x 4,15,647x 79,404x
EV / Revenue 2,42,134x 4,16,129x 46x 3,70,592x 70,790x
EV / EBITDA -11x -3.02x -2.21x -6.26x -3.51x
EV / EBIT -10.5x -2.97x -2.18x -6.11x -3.44x
EV / FCF - - - - -
FCF Yield - - - - -
Dividend per Share 2 - - - - -
Rate of return - - - - -
EPS 2 -0.1869 -0.4668 -0.459 -0.206 -0.255
Distribution rate - - - - -
Net sales 1 0.000039 0.000022 0.2 0.000046 0.000188
EBITDA 1 -0.8584 -3.031 -4.174 -2.723 -3.786
EBIT 1 -0.9019 -3.083 -4.23 -2.79 -3.873
Net income 1 -0.9782 -2.443 -3.745 -2.081 -3.318
Net Debt 1 -3.12 -1.131 -2.467 -2.073 -1.619
Reference price 2 2.4000 1.9650 1.4400 1.9700 1.1780
Nbr of stocks (in thousands) 5,235 5,235 8,107 9,705 12,672
Announcement Date 29/04/22 28/04/23 14/04/25 14/04/25 27/04/26
1EUR in Million2EUR
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 1.2Cr
33.56x8.38x25.87x0.05% 5.73TCr
20.68x6.37x13.94x1.54% 5.5TCr
-41.86x13.29x-39.17x-.--% 2.32TCr
-17.88x4.15x-7.26x-.--% 2.26TCr
25.74x5.04x13.35x-.--% 2.05TCr
24.54x4.77x15.5x-.--% 1.76TCr
-787.21x37.41x-4211.77x-.--% 1.57TCr
43.58x17.61x45.34x0.08% 1.45TCr
17.42x5.04x11.77x-.--% 1.39TCr
Average -75.71x 11.34x -459.16x 0.19% 2.4TCr
Weighted average by Cap. -36.72x 9.70x -264.23x 0.37%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. ALNFL Stock
  4. Valuation NFL Biosciences